Drug Type Small molecule drug |
Synonyms FNX010 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metabolic dysfunction-associated steatotic liver disease | Phase 1 | China | 25 Mar 2026 | |
| Metabolic Dysfunction Associated Steatohepatitis | Preclinical | China | 30 Nov 2022 |





